Evaluation of bone mineral density and bone turnover markers in Egyptian children with juvenile rheumatoid arthritis

Archives of Medical Science

Volumn 5, Issue 3, 2009, Pages 434-442

  Kandil, Manal E ^a   Mourad, Abbass ^a   El Hamshary, Azza ^b   Hussein, Gehan ^b   Ahmed, Azza ^a   Mawgoud, Sohair Abdel ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

BMD; Children; DXA; Juvenile rheumatoid arthritis; Osteoporosis; Osteoprotegrin; RANKL

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; DEOXYPYRIDINOLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EGYPT; FEMALE; FEMUR NECK; FRACTURE; HIGH RISK POPULATION; HUMAN; JOINT LIMITATION; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LUMBAR SPINE; MALE; OSTEOPOROSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 73449124776     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE (eds.). Textbook of pediatric rheumatology. Fourth ed. New York: Churchill Livingston 2001; 113-219.
2. Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 1232-9.
3. Mikuls TR, Saag KG, Curtis J, et al. Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethnic-specific normative data. J Natl Med Assoc 2005; 97: 1155-60.
4. Hartmanm C, Shamir R, Esbach-Adiv O, Iosilevsky G, Brik R. Assessment of osteoporosis by quantitative ultrasound versus dual-energy X-ray absorptiometry in children with chronic rheumatic diseases. J Rheumatol 2004; 31: 981-5.
5. McDonaugh JE. Osteoporosis in juvenile idiopathic arthritis. Curr Opin Rheumatol 2001; 13: 399-404.
6. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995; 54: 49-52.
7. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13: 777-87.
8. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-37.
9. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 3597-602.
10. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
11. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
12. Hofbauer LC, Heufelder AE. The role of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001; 44: 253-9.
13. Tsuda E, Goto M, Michizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234: 137-42.
14. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-53.
15. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.
16. Geusens PP, Landewé RB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheumat 2006; 54: 1772-7.
17. Sagges G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: Diagnosis, risk factors, and prevention. J Pediatr Endocrin Metabol 2001; 14: 833-9.
18. Goldring SR. Inflammatory mediators as essential elements in bone modelling. Calcif Tissue Int 2003; 73: 97-100.
19. Arnett F, Edworthy S, Bloch D. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. Tanner JM. Growth at adolescence. 2nd ed. Oxford: Blackwell Scientific Publications 1962; 28-39.
21. Leonard MB, Propert KJ, Zemel BS, Stallings VA, Feldman HI. Discrepancies in pediatric bone mineral density reference data: potential for misdiagnosis of osteopenia. J Pediatr 1999; 135: 182-8.
22. Power MJ, Fottrel PF. Diagnostic methods and clinical applications. Crit Rev Lab Sci 1991; 28: 287-335.
23. Garnero P, Delmas PD. Clinical usefulness of markers of bone remodeling in osteoporosis. In: Meunier PJ (ed.). Osteoporosis: Diagnosis and management. Martin Dunitz, London 1998; 79-101.
24. Sagges G, Bertelloni S, Baroncelli GI, Di Nero G. Serum levels of carboxy-terminal peptide of type I procollagen in healthy children from first year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 1992; 151: 764-8.
25. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002; 8: 2306-10.
26. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: Report of the UK consensus group. QJM 1998; 91: 71-92.
27. Van der Heijde DM, van't hot MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990; 49: 916-20.
28. Henderson CJ, Specker BL, Sierra RI, Campaigne BN, Lovell DJ. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis: Frequency of osteopenia and contributing factors. Arthritis Rheum 2000; 43: 531-40.
29. Celiker R, Bal S, Bakkaloǧlu A, et al. Factors playing a role in the development of decreased bone mineral density in juvenile chronic arthritis. Rheumatol Int 2003; 23: 127-9.
30. Lien G, Flatoø B, Haugen M, et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: A long-term outcome study of one hundred five patients. Arthritis Rheum 2003; 48: 2214-23.
31. Lien G, Selvaag AM, Flatø B, et al. A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic srthritis. Arthritis Rheum 2005; 52: 833-40.
32. Kashef S, Saki F, Karamizadeh Z, Kashef MA. Bone mineral density in children with systemic lupus erythematosus and juvenile rheumatoid arthritis. Ann Saudi Med 2007; 27: 427-31.
33. Pepmueller PH, Cassidy JT, Allen SH, Hillman LS. Bone mineralization and bone mineral metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 1996; 39: 746-757.
34. Frost HM, Schonau E. The muscle-bone unit in children and adolescents: a 2000 overview. J Pediatr Endocrinol Metab 2000; 13: 571-90.
35. Sasaki N, Kusano E, Ando Y, Yano K, Tsuda E, Asano Y. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 2001; 16: 479-82.
36. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. Endocrinology 2006; 147: 3613-22.
37. Kotaniemi A. Growth retardation and bone loss as determinants of axial osteopenia in juvenile chronic arthritis. Scand J Rheumatol 1997; 26: 14-8.
38. Rabinovich CE. Bone mineral status in juvenile rheumatoid arthritis. J Rheumatol 2000; 27 Suppl 58: 34-7.
39. Kotaniemi A, Savolainen A, Kroger H, Kautiainen H, Isomaki H. Weight-bearing physical activity, calcium intake, systemic glucocorticoids, chronic inflammation, and body constitution as determinants of lumbar and femoral bone mineral in juvenile chronic arthritis. Scand J Rheumatol 1999; 28: 19-26.
40. Buzi F, Maccarinelli G, Guaragni B, et al. Serum osteoprotegerin and receptor activator of nuclear factors kappa B (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. Clin Endocrinol (Oxf) 2004; 60: 87-91.
41. Masi L, Simonini G, Piscitelli E, et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/ RANK-L in bone injury? J Rheumatol 2004; 31: 986-91.
42. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum 2002; 46: 1744-53.
43. Feuerherm AJ, Borset M, Seidel C, et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 229-34.
44. Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004; 31: 1483-90.
45. Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007; 195: e135-41.
46. Lee C, Lee EY, Chung SM, Mun SH, Yoo B, Moon H. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum 2004; 50: 3831-43.
47. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone dsease assessment. J Clin Endocrinol Metabol 2005; 90: 6323-31.
48. Varsani H, Patel A, van Kooyk Y, Wool P, Wedderburn LR. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). Rheumatology 2003; 42: 583-90.
49. Kotake S, Udagawa N, Hakoda M, et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 2001; 44: 1003-12.
50. Wu Y, Liu J, Feng X, et al. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous arthritis. Arthritis Rheum 2005; 52: 3257-68.
51. Liu H, Liu K, Bodenner DL. Estrogen receptor inhibits interlukin-6 gene expresion by disruption of nuclear factor kappa B transactivation. Cytokine 2005; 31: 251-7.
52. Hillman L, Cassidy JT, Johnson L, Lee D, Allen SH. Vitamin D metabolism and bone mineralization in children with juvenile rheumatoid arthritis. J Pediatr 1994; 124: 910-6.
53. Oelzner P, Franke S, Lehmann G, et al. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 2007; 26: 2127-35.
54. Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003; 6: 295-9.
55. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992; 75: 1060-5.
56. Bonjour JP, Theintz G, Buchs B, Slosman D, Rizzoli R. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991; 73: 555-63.
57. El-Hajj FG, Badddoura R, Awada, H, Salam N, Salamoun M, Rizk P. Low peak bone mineral density in healthy Lebanese subjects. Bone 2002; 31: 520-8.
58. Seibel MJ. Biochemical markers of bone turnover. Part II: Clinical applications in the management of osteoporosis. Clin Biochem Rev 2006; 27: 123-38.
59. Lovell DJ, Glass D, Ranz J, et al. A randomized controlled trial of calcium supplementation to increase bone mineral density in children with juvenile rheumatoid arthritis. Arthritis Rheum 2006; 45: 2235-42.
60. Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics 2008; 121: e1585-90.
61. Watała C. Sample size and significance - somewhere between statistical power and judgment prostration. Arch Med Sci 2007; 3: 5-13.